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Influence of carrier (polymer) type and drug-carrier ratio in the development of
amorphous dispersions for solubility and permeability enhancement of ritonavir.
Abstract
The influence of the ratio of Eudragit® L100-55 or Kolliphor® P188 on the solubility, dissolution, and
permeability of ritonavir was studied with a goal of preparing solid dispersions (SDs) of ritonavir. SDs
were formulated using solvent evaporation or lyophilization techniques, and evaluated for their physicalchemical properties. The dissolution and permeability assessments of the functionality of the SDs were
carried out. The preliminary functional stability of these formulations was assessed at accelerated
storage conditions for a period of six months. Ritonavir: Eudragit® L100-55 (RE, 1:3) SD showed a 36-fold
higher solubility of compared with pure ritonavir. Similarly, ritonavir:Kolliphor® P188 (RP, 1:2) SD exhibited
a 49-fold higher solubility of ritonavir compared to pure ritonavir. Ritonavir dissolution from RE
formulations increased with increasing ratios of Eudragit® L100-55, upto a ritonavir:carrier ratio of 1:3.
The ritonavir dissolution from RP formulations was highest at a ritonavir:Kolliphor® P188 ratio of 1:2.
Dissolution efficiencies of these formulations were found to be in line with, and supporting the dissolution
results. The permeability of ritonavir across the biological membrane from the optimized formulations RE
(1:3) and RP (1:2) were ~76 % and ~97 %, respectively; and were significantly higher compared to that of
pure ritonavir (~20 %). A preliminary (six-month) stability study demonstrated the functional stability of
prepared solid dispersions. The present study demonstrates that a good solubility, dissolution, and
permeability improvement of ritonavir can be achieved with a careful choice of the carrier polymer, and by
optimizing the amount of the chosen polymer in an SD formulation.
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ABSTRACT
The influence of the ratio of Eudragit® L100-55 or Kolliphor® P188 on the solubility, dissolution, and
permeability of ritonavir was studied with a goal of preparing solid dispersions (SDs) of ritonavir. SDs were
formulated using solvent evaporation or lyophilization techniques, and evaluated for their physical-chemical
properties. The dissolution and permeability assessments of the functionality of the SDs were carried out. The
preliminary functional stability of these formulations was assessed at accelerated storage conditions for a
period of six months. Ritonavir: Eudragit® L100-55 (RE, 1:3) SD showed a 36-fold higher solubility of
compared with pure ritonavir. Similarly, ritonavir:Kolliphor® P188 (RP, 1:2) SD exhibited a 49-fold higher
solubility of ritonavir compared to pure ritonavir. Ritonavir dissolution from RE formulations increased with
increasing ratios of Eudragit® L100-55, upto a ritonavir:carrier ratio of 1:3. The ritonavir dissolution from RP
formulations was highest at a ritonavir:Kolliphor® P188 ratio of 1:2. Dissolution efficiencies of these
formulations were found to be in line with, and supporting the dissolution results. The permeability of
ritonavir across the biological membrane from the optimized formulations RE (1:3) and RP (1:2) were ~76 %
and ~97 %, respectively; and were significantly higher compared to that of pure ritonavir (~20 %). A
preliminary (six-month) stability study demonstrated the functional stability of prepared solid dispersions. The
present study demonstrates that a good solubility, dissolution, and permeability improvement of ritonavir can
be achieved with a careful choice of the carrier polymer, and by optimizing the amount of the chosen polymer
in an SD formulation.
KEY WORDS: Ritonavir, solid-dispersion, solubility, dissolution, permeability

INTRODUCTION

Poor aqueous solubility, and rate-limited
dissolution or absorption has resulted in
low/variable bioavailability for most new drug

*

Corresponding author: Nishikant A. Raut, Department of
Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur
University, Nagpur, India, 440033, Tel: +91 942 280 3768,
E-mail: nishikantraut29@gmail.com
**
Both authors contributed equally

This Journal is © IPEC-Americas Inc

molecules discovered using relatively modern
approaches such as combinatorial chemistry
and high throughput screening (1). Drugs
developed by such methods possess requisite
pharmacological properties, however, the
efficacy of such drugs remains a matter of
concern. Therefore, it becomes imperative to
explore innovative formulation technologies to
enhance the solubilization rate of drugs with

September 2017

J. Excipients and Food Chem. 8 (3) 2017 -

75

Original Article
poor aqueous solubility for successful
incorporation into orally bioavailable and
therapeutically effective formulations (2, 3).
Several approaches for improving the solubility
of such molecules have been explored
previously (4). Formulating amorphous
dispersions of such drugs, using one or more
carrier polymers, is among the popular
approaches used to improve the dissolution of
poorly soluble drugs. Solid dispersions are
uniform dispersions of one, or more,
pharmacologically active molecule(s) in an inert
carrier/matrix, usually prepared by techniques
such as solvent-evaporation, melting, freezedrying, spray-drying, etc. (5).
Ritonavir, a BCS class II drug (poor aqueous
solubility/high permeability), is known to
exhibit low/variable oral bioavailability (6).
Published literature reports several approaches
to improve the solubility/dissolution profile of
ritonavir via formulating it into solid
dispersions (7-9). However, most attempts of
formulating solid dispersions of ritonavir have
some lacunae. Law et al. prepared and evaluated
ritonavir solid dispersions using polyethylene
glycol (PEG 8000) as a carrier by solventevaporation and vacuum drying (8, 9). A major
shortcoming of these studies is the use of high
ritonavir:carrier ratio (1:9) with a ritonavir dose
of 100 mg, resulting in a total mass of 1000 mg
(excluding other excipients). The development
of an oral solid dosage form with such a
formulation will add to the bulk, making it an
unfeasible endeavor. Sinha et al. attempted to
overcome this issue by preparing solid
dispersions of ritonavir using Gelucire® as a
carrier polymer. This study was a relative
improvement over the previous studies in that
it used a ritonavir: carrier ratio of 1:4, and
demonstrated an enhancement in the
dissolution of ritonavir.
The presented study was initiated with a goal of
exploring the feasibility of further reducing the
amounts of carrier used to prepare solid
dispersions of ritonavir, while increasing its
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solubility, dissolution, and permeability. Two
polymers viz. Eudragit® L100-55 or Kolliphor®
P188 were chosen as potential carrier-matrices
in the formulation of ritonavir dispersions.
Ritonavir is known to cause gastric acidity and
abdominal pain (10). Eudragit® L100-55 is an
enteric polymer known to promote drug
solubilization and release at pH above 5.5 and
would therefore be an appropriate choice as a
carrier. Ritonavir is also infrequently associated
with bleeding of the stomach or intestines (10).
Kolliphor® P188 is reported to have an
interesting and useful property of repairing
damaged biological membranes (11, 12). Thus,
considering the side effects of ritonavir and the
reported beneficial properties of Kolliphor®
P188, it was selected as another carrier matrixformer for the formulation of ritonavir
dispersions.
The dispersions of ritonavir with Eudragit®
L100-55 (RE) or Kolliphor® P188 (RP) were
formulated using solvent evaporation or
lyophilization methods. The prepared
dispersions were initially characterized for their
physical-chemical properties. This initial
characterization of the dispersions was followed
by an analysis of their functionality via
dissolution and permeability analysis.
Additionally, the influence of food on the
functionality of the optimized formulations
were evaluated via dissolution studies
conducted under fasted and fed conditions.
Finally, the functional stability of the optimized
formulations assessed in a 180-day, controlled
stability study.
MATERIALS AND METHODS
Materials
Ritonavir was obtained from Emcure
Laboratories Pvt. Ltd., Pune, India. Eudragit®
L100-55 was obtained from Evonik Degussa
India Pvt. Ltd., Mumbai, India. Kolliphor®
P188 was obtained from BASF India Ltd.,
Mumbai, India. ‘Krebs solution’ and the
required dissolution media were prepared in the
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laboratory. Analytical grade chemicals were
used for all experiments.
Preparation of solid dispersions
Ritonavir-Eudragit® L 100-55 solid dispersion
(RE)

Solid dispersions (RE) of ritonavir and
Eudragit® L100-55 in different ratios (Table 1)
were prepared using a solvent evaporation
method described earlier by Tran et al. (13).
Briefly, ritonavir and Eudragit® L100-55 were
dissolved separately in ethanol, and the
resulting solutions were mixed in a porcelain
dish. This mixture was subjected to ultrasonication (10 minutes) to ensure miscibility of
both solutions. The solvent was evaporated by
placing the mixture in an oven (50°C) for a
period of 48 hours. The resulting solid
dispersion (a thin, transparent film) was milled
to a fine powder.
Ritonavir-Kolliphor® P188 solid dispersion (RP)

Solid dispersions (RP) of ritonavir and
Kolliphor® P188 in different ratios (Table 1)
were prepared using a freeze-drying technique
reported earlier by Sonar et al. (14). Briefly,
ritonavir and Kolliphor® P188 were dissolved
separately in ethanol. The drug solution, and
the polymer solution were blended in a
porcelain dish. This mixture was subjected to
ultra-sonication (10 minutes) to ensure that
both solutions are homogeneously blended.
The mixture was lyophilized at -50°C and 4000
mbar pressure using a bench-top freeze-dryer
(Model: Lyodel, Delvac Pumps Pvt. Ltd.,
Chennai, India) for 24 hours. A uniform soliddispersion powder was obtained after particle
size reduction of the product obtained above.
Physical-chemical properties of the prepared
dispersions
Solubility analysis

The saturation solubility of pure ritonavir and
the prepared solid dispersions was carried out

This Journal is © IPEC-Americas Inc

using a shake-flask technique reported earlier
(4). Briefly, excess amount of ritonavir or the
prepared solid-dispersion (~10 mg pure
ritonavir) was placed in glass vials containing 10
ml of water (for RP), or phosphate buffer (pH6.8 for RE). These test solutions were stirred
(100 RPM) on a rotary shaker (Model: RS-24
BL, Remi Laboratory Instruments, Goregaon
(E), Mumbai, India) at 37°C for 48 hours.
Aliquots (5 ml) of samples were withdrawn at
48 hours, and filtered using a cellulose acetate
filter (pore size 0.45 μM for ritonavir and 0.22
μM for the prepared dispersion, EMD
Millipore®, Billerica, MA). The filtered samples,
after suitable dilutions, were analyzed for
ritonavir concentration at spectrophotometric
wavelength of 239 nm.
Particle size and zeta potential analysis

The micromeritic properties of the dispersion
samples was carried out using photon
correlation spectroscopy on a laser diffraction
particle size analyzer (Model: Nano Partica SZ100, Horiba Instruments Pvt. Ltd., Singapore).
The details of the procedure has been reported
previously (7). The zeta potential for measuring
the electrophoretic mobility of the prepared
solid-dispersions was estimated using the
Smoluchowski equation (15). Three
independent sample replicates were used for all
measurements.
Photomicroscopy

The morphology of pure ritonavir and the
prepared solid-dispersions was primarily
characterized by photomicroscopy. Briefly, a
dispersion of pure ritonavir or the prepared
solid-dispersions (~10 mg pure ritonavir) in 5
ml distilled water was prepared in glass vials.
The aqueous dispersions were shaken gently,
and the suspended particles were mounted on
glass slides. The photomicrographs of the
samples were captured with a microscope
equipped with a digital camera (Model: DM
2500, Leica Microsystems, Germany).
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Thermal analysis

The thermal behavior of pure ritonavir,
Eudragit® L100-55, Kolliphor® P188, the
physical mixtures of ritonavir with Eudragit®
L100-55 or Kolliphor® P188, and the prepared
solid dispersions was determined by differential
scanning calorimetry (DSC). Procedural details
of the preparation has been reported previously
(16, 17).
Fourier-transform infrared (FTIR) spectroscopy

A FTIR spectrophotometer (Model: IR
Prestige-21, Shimadzu, Japan) was used for the
infrared spectral analysis of pure ritonavir,
Eudragit® L100-55, Kolliphor® P188, the
physical mixtures of ritonavir with Eudragit®
L100-55 or Kolliphor® P188, and the prepared
solid dispersions. All samples, before subjecting
to FTIR analysis, were vacuum-dried to ensure
removal of any residual moisture. 45 scans at a
resolution of 4 cm!1 were carried out for each
sample. The measurements were made in the
wavelength range of 4000 to 600 cm!1.
X-ray diffractometry

evaluation

of

the

ritonavir

Ritonavir dissolution

The dissolution studies of pure ritonavir and
the prepared solid-dispersions were conducted
using a dissolution apparatus (USP Type II,
paddle method, Model: TDT-08LX, Electrolab
India Pvt. Ltd., Mumbai, India) equipped with

This Journal is © IPEC-Americas Inc

To further analyze their dissolution
performance, the dissolution efficiencies (DE)
of pure ritonavir and the prepared soliddispersions were computed and compared,
using the dissolution results. The dissolution
efficiencies were estimated using the
relationship proposed by Anderson et al. (18)
Fasted versus fed state dissolution

The crystal state analysis of the samples, i.e.
pure ritonavir, Eudragit® L100-55, Kolliphor®
P188, the physical mixtures of ritonavir with
Eudragit® L100-55 or Kolliphor® P188, and the
prepared solid dispersions were carried out on a
powder x-ray diffractometer (Model: D8
Phaser, Bruker AXS, Inc., Madison, WI, USA).
The details of the procedures have been
published previously (7, 16).
Performance
dispersions

Elab Disso Lite software, at 37°C and a stirring
rate of 50 RPM. The dissolution medium for
RE consisted of HCl (0.1N, pH-1.2) for the
first two hours, followed by a phosphate buffer
(0.05M, pH-6.8) for the remaining duration of
the study. The dissolution medium for RP was
phosphate buffer (0.05M, pH-6.8). Accurately
weighed amounts of pure ritonavir (50 mg), or
the prepared solid-dispersions (~50 mg
ritonavir) were added to the dissolution media
separately, and aliquots were withdrawn at
predetermined intervals. The withdrawn
samples were membrane-filtered (pore size 0.45
μM for ritonavir and 0.22 μM for the prepared
dispersion) and after suitable dilutions, analyzed
at a spectrophotometric wavelength of 239 nm
against the blank.

The food effects on the absorption of ritonavir
from the prepared solid-dispersions were
evaluated in Fasted-State Simulated Intestinal
Fluid (FaSSIF) and Fed-State Simulated
Intestinal Fluid (FeSSIF) dissolution media.
The details of the methods followed for the
preparation of blank FaSSIF and FeSSIF media
have been reported previously (19). The
dissolution was carried out using a standard
dissolution apparatus (USP type II, paddle
method, Model: TDT- 08LX Electrolab India
Pvt. Ltd., Mumbai, India) in FaSSIF (500 ml) or
FeSSIF (1000 ml) media at 37 ± 0.5°C, using a
stir rate of 50 RPM. Samples (5 ml) were
withdrawn at 15 minute time intervals,
membrane-filtered (pore size 0.45 μM for
ritonavir and 0.22 μM for the prepared
dispersion), and analyzed spectrophoto-
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metrically at 251 nm (for FaSSIF), or 305 nm
(for FeSSIF).
Ritonavir permeability

The ritonavir permeability from the prepared
solid-dispersions was assessed using everted rat
intestine technique as reported previously (7,
16, 20). The Institutional Animal Ethics
Committee (IAEC) approved the use of
experimental animals in the study. The
permeability of ritonavir from the formulated
solid dispersions was estimated by
spectrophotometrically analyzing the samples
collected every 15 minutes, at 239 nm.
Preliminary functional stability assessment

The functional stability of the optimized soliddispersions was assessed by storing the samples
for six months at accelerated conditions of
temperature and humidity. The samples were
stored at 25 ± 2ºC and 60 ± 5% RH. The
formulations in tightly-closed, light-resistant
high-density polyethylene (HDPE) vials were
placed in controlled-conditions stability
chambers for 180 days. At the end of storage,
the samples were assessed for the dissolution
and permeability of ritonavir (21-23).
RESULTS AND DISCUSSION
Physical-chemical properties of the prepared
dispersions
Saturation solubility

The results of the aqueous solubilities of
ritonavir alone and the formulated solid
dispersions with Eudragit® L 100-55 (RE) or
Kolliphor® P188 (RP) are shown in Table 1.
Pure ritonavir was found to be practically
insoluble in water (0.37 ± 0.03 µg/ml) or pH6.8 phosphate buffer (0.39 ± 0.04 µg/ml). The
solubility of ritonavir in RE solid-dispersion
increased with the increasing Eudragit® L 10055 ratio up to 1:3 (ritonavir:Eudragit® L 10055). The optimized RE solid-dispersion
demonstrated a significant increase (36-times)
This Journal is © IPEC-Americas Inc

in the aqueous solubility of ritonavir. Similarly,
the solubility of ritonavir in RP solid-dispersion
increased with the increasing Kolliphor® P188
ratio upto 1:2 (ritonavir:Kolliphor® P188). This
RP formulation showed a significant increase
(49-fold) in the aqueous solubility of ritonavir.
The observed increase in the solubility of
ritonavir may be caused by a reduction in the
molecular crystallinity (partial amorphization)
of ritonavir in the prepared solid-dispersions
(7).
Table 1 Saturation solubility of pure ritonavir, and
ritonavir in the prepared solid dispersions
RITONAVIR SOLUBILITY (μg/ml)*
DRUG:
RITONAVIR:
CARRIER
RITONAVIR: EUDRAGIT® L 100-55
KOLLIPHOR® P188
RATIO
(in PBS pH 6.8)
(in water)
Pure
Ritonavir

0.39 ± 0.04

0.37 ± 0.03

1:1

7.54 ± 0.07

15.31 ± 0.07

1:2

12.16 ± 0.04

18.15 ± 0.09

1:3

14.09 ± 0.07

13.39 ± 0.04

1:4

10.81 ± 0.06

9.61 ± 0.07

*Values represent mean ± Std. Dev. (n=3)

Micromeritic
dispersions

properties

of

the

prepared

Figure 1 shows the particle size distribution and
zeta potential analysis of optimized RE (Figure
1A) and RP (Figure 1B). The mean particle size
of the optimized RE (Figure 1Aa) solid
dispersions was 305.6 ± 16.3 nm. The mean
particle size of the optimized RP solid
dispersions (Figure 1Ba) was observed to be
323.7 ± 17.6 nm. The surface area/volume
(SA/V) ratio for most pharmaceutically
processed materials is inversely proportional to
their particle size (24). The small particle size of
the optimized solid dispersions facilitates an
easier release of the Active Pharmaceutical
Ingredient (API) from the formulation via
diffusion and/or surface erosion. Moreover,
the smaller particle size of prepared solid
dispersions also facilitates the transport across
biological drug barriers (25, 26).
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The figure compares the surface architecture of
ritonavir (Figure 2A) with that of RE (Figure
2B) and RP (Figure 2C) at 20x magnification.
The small, needle shaped crystalline particles of
ritonavir (Figure 2A), corresponding to the
polymorphic form III of ritonavir have been
reported earlier (28). A dramatically different
morphology was observed with both, RE and
RP solid-dispersions. RE appeared transparent,
large, sharp-edged, flat particles with a rough
surface: whereas RP appeared relatively
irregularly shaped, smooth/rounded-edged
particles. The needle-shaped crystals of pure
ritonavir were absent in images of RE and RP.
These observations supported the formation of
solid-dispersions.
Thermal analysis

Figure 1 Particle size distribution (a) and zeta potential
profiles (b) of ritonavir:Eudragit® L100-55 (A) and
ritonavir:Kolliphor® P188 (B) solid dispersions.

Zeta potential, a commonly measured property
of solid-dispersions, correlates to the surface
interactions and points to the physical stability
of micro- or nano-particulate formulations. The
zeta potential of the optimized RE was -36.2 ±
2.3 mV (Figure 1Ab) and that of the optimized
RP (Figure 1Bb) was -38.8 ± 1.9 mV. These
observed values are indicative of an acceptable
physical stability of the prepared solid
dispersions, and similar to those reported
earlier (27).

The analysis of any drug-drug, drug-excipient,
and/or excipient-excipient interactions in a
formulation are often carried out using thermal
techniques. Figure 3A compares the DSC
profiles of (a) pure ritonavir, (b) pure Eudragit®
L100-55, (c) the physical mixture (PM, 1:1) of
ritonavir and Eudragit® L100-55, and (d) the
solid dispersion of ritonavir with Eudragit®
L100-55 (RE). As shown in Figure 3Aa, the
DSC curve of pure ritonavir revealed a single,
sharp endothermic peak around ~125ºC
(melting point of ritonavir). Similar
observations have been reported earlier (28).
The thermogram of Eudragit® L100-55 (Figure
3Ab) was devoid of any significant event.
However, a broad endothermic event, observed
at around ~170-175°C, is most likely indicative
of the beginning of the decomposition of
Eudragit® L100-55 (29). The DSC profile of the
PM (Figure 3Ac) exhibited a pattern of weak

Photomicroscopy

Figure 2 (A, B, and C) shows the microscopically observed dimensional characteristics
of ritonavir particles and the SD formulations.

This Journal is © IPEC-Americas Inc

Figure 2 Photomicroscopy images of (A) pure ritonavir,
(B) ritonavir:Eudragit® L100-55 solid dispersion, and (C)
ritonavir:Kolliphor® P188 solid dispersions.
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from the peaks obtained with pure ritonavir,
Eudragit® L100-55, or their physical mixture,
suggesting possible interactions between
ritonavir and Eudragit® L100-55, resulting in
the formation of an amorphous aggregate.
Moreover, the sharp melting peak of ritonavir
was absent in the thermogram of RE, thus
supporting the possible amorphization of
ritonavir (1).

Figure 3 (A) Comparison of the DSC thermograms of (a)
pure ritonavir, (b) pure Eudragit® L100-55, (c) the physical
mixture (PM) of ritonavir and Eudragit® L100-55, and (d)
the solid dispersion of ritonavir with Eudragit® L100-55
(RE). (B) Comparison of the DSC thermograms of (a) pure
ritonavir, (b) pure Kolliphor® P188, (c) the physical mixture
(PM) of ritonavir and Kolliphor® P188, and (d) the solid
dispersion of ritonavir with Kolliphor® P188 (RP).

endothermic peaks that can be associated with
both, ritonavir and Eudragit® L100-55. The
melting peak of ritonavir in the mixture was
weaker than that observed with pure ritonavir.
The lower quantitative ratio of ritonavir in the
mixture, as well as possible in situ interactions
between ritonavir and Eudragit® L100-55 were
likely contributors to these observations. Figure
3Ad shows the thermogram of the prepared
solid dispersion of ritonavir with Eudragit®
L100-55 (RE). This thermogram revealed very
weak and undefined peak at ~70°C. This peak
differed in the location of the temperature scale

This Journal is © IPEC-Americas Inc

Figure 3B compares the DSC profiles of (a)
pure ritonavir, (b) pure Kolliphor® P188, (c) the
physical mixture (PM, 1:1) of ritonavir and
Kolliphor® P188, and (d) the solid dispersion of
ritonavir with Kolliphor® P188 (RP). The
thermogram of pure ritonavir (Figure 3Ba) was
similar to the one observed before, with a
single, sharp melting endotherm (~125°C)
characteristic of crystalline material. The
thermogram of Kolliphor® P188 (Figure 3Bb)
also showed a single, sharp endotherm
approximately between 50-55°C. This peak is
characteristic of poloxamer melting point, and
consistent with previously reported
observations (30). The thermogram of PM
(Figure 3Bc) revealed the poloxamer melting
peak between 50-55°C. The ritonavir melting
peak (125°C) was absent in this thermogram.
Only an insignificant remnant, in the form of a
broad, undefined, endothermic curve was
observed between ~110-125°C. This
disappearance of ritonavir melting peak can be
attributed to the in situ molecular dispersion of
ritonavir into the molten Kolliphor® P188. The
thermogram of ritonavir-Kolliphor® P188 solid
dispersion (RP) (Figure 3Bd) showed, as
expected, a single, sharp endothermic peak
representing Kolliphor® P188 melting; whereas
the melting peak of ritonavir was absent. These
observations support a successful formation of
molecular aggregates of ritonavir and
Kolliphor® P188 in the prepared solid
dispersion.
Fourier transform infrared (FTIR) analysis

Figure 4 shows the FTIR spectra of (A) pure
ritonavir, (B) Eudragit® L100-55, (C) PM, and
(D) the solid dispersion of ritonavir with
Eudragit® L100-55 (RE), respectively. The
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Figure 4 FTIR spectra of (A) pure ritonavir, (B) Eudragit® L100-55, (C) PM, and (D) the solid dispersion of ritonavir with
Eudragit® L100-55 (RE).

spectrum of pure ritonavir (Figure 4A)
exhibited molecule-specific peaks similar to
those reported earlier (7). The FTIR spectrum
of Eudragit® L100-55 is shown in the Figure
4B. This spectrum revealed a broader band,
characteristic of a hydroxyl group (O-H stretch
vibration) at 2358 cm-1, a strong peak related to
the carbonyl group (C-O stretch vibration) at
1733 cm-1, and two bands at 1368 cm-1 and
1266 cm-1 related to ester linkages (C-O stretch
vibration). The spectrum of PM (Figure 4C)
showed peaks characteristic of both the
individual components of the mixture i.e., pure
ritonavir and Eudragit® L100-55. Figure 4D
shows the FTIR spectrum of the prepared solid
dispersion of ritonavir with Eudragit® L100-55
(RE). This spectrum was devoid of the key
peaks viz. 3116 cm-1, 2972 cm-1 and 2852 cm-1,
associated with ritonavir. The absence of
ritonavir peaks in the FTIR spectrum of the
prepared solid dispersion indicated the
interaction of ritonavir with Eudragit® L100-55
at a molecular level. The ritonavir molecules
likely dispersed within Eudragit® L100-55
matrix.

This Journal is © IPEC-Americas Inc

Figure 5 compares the FTIR spectra of (A)
pure ritonavir, (B) pure Kolliphor® P188, (C)
the physical mixture (PM) of ritonavir and
Kolliphor® P188, and (D) the solid dispersion
of ritonavir with Kolliphor® P188 (RP). The
spectrum of pure ritonavir (Figure 5A) revealed
all the characteristic peaks of ritonavir
described above. The spectrum of Kolliphor®
P188 (Figure 5B) exhibited absorption peaks at
2886 cm-1 and 1546 cm-1 related to O-H and CO stretching, respectively. This spectrum also
showed additional peaks at 1467 cm-1, 1359 cm1
, 1278 cm-1, 954 cm-1, and 842 cm-1. Figure 5C
shows the spectrum of the physical mixture
(PM). This spectrum revealed that all the peaks
associated with ritonavir and Kolliphor® P188
were retained, indicating a lack of any
interaction between the components. The
spectrum of the ritonavir-Kolliphor® P188 solid
dispersion (Figure 5D) was devoid of the
characteristic peaks associated with either
component. Moreover, two additional peaks
were observed at 3502 cm-1 and 2880 cm-1, in
this spectrum. Hydrogen bonding between the
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Figure 5 FTIR spectra of (A) pure ritonavir, (B) Kolliphor® P188, (C) PM, and (D) the solid dispersion of ritonavir with
Kolliphor® P188 (RP).

components of solid dispersion may have
resulted in the appearance of these peaks.
These observations support our inference of
molecular dispersion of ritonavir within
Kolliphor® P188 matrix.
X-ray diffractometry

The solid-state properties of the prepared solid
dispersions (RE and RP), compared with pure
ritonavir, were further examined using powder
x-ray diffractometry (PXRD). Figure 6 shows
the x-ray diffractograms of (A) pure ritonavir,
(B) the solid dispersion of ritonavir with
Eudragit® L100-55 (RE), and (C) the solid
dispersion of ritonavir with Kolliphor® P188
(RP). The diffractograms are plotted in the
form of intensity (counts) on a 2θ scale. The
diffractogram of pure ritonavir (Figure 6A)
revealed several sharp peaks, characteristic of
its crystalline nature, in the region of 5-50° 2θ.
These observations are in agreement with those
reported earlier in the literature (7, 28). Figure
6B shows the diffractogram of the prepared
solid-dispersion of ritonavir with Eudragit®
L100-55 (RE). This diffractogram exhibited a

This Journal is © IPEC-Americas Inc

single, broad, and undefined peak (halo),
typically associated with amorphous materials.
Most of the characteristic crystalline peaks of
ritonavir were absent. Similarly, in the
diffractogram of the solid dispersion of
ritonavir with Kolliphor® P188 (RP) (Figure
6C) was devoid of most of the crystalline peaks
of ritonavir. Only two peaks viz. at 19 2θ and 23
2θ, which can be attributed to ritonavir were
observed. These observations led us to infer
that in the ritonavir- Kolliphor® P188 (RP),
ritonavir is at least partially amorphized.
Overall, these results support a reduction in
ritonavir crystallinity, and its partial
amorphization.
Performance
dispersions

evaluation

of

the

ritonavir

Ritonavir dissolution

Figure 7 compares the dissolution profiles
(ritonavir release, %) of pure ritonavir, with that
of the prepared solid dispersions of ritonavir,
with different ratios of Eudragit® L100-55
(Figure 7A, RE-1 to RE-4) or Kolliphor® P188
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Figure 6 X-ray diffractograms of (A) pure ritonavir, (B) the solid dispersion of ritonavir
with Eudragit® L100-55 (RE), and (C) the solid dispersion of ritonavir with Kolliphor®
P188 (RP).
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Figure 7 In vitro dissolution profiles of pure ritonavir and
the solid dispersions of ritonavir with different ratios of (A)
Eudragit® L100-55 or (B) Kolliphor® P188.

(Figure 7B, RP-1 to RP-4). The dissolution of
RE formulations was carried out in HCl (0.1N,
pH-1.2) for the first two hours, followed by
phosphate buffer (0.05M, pH-6.8) for an
additional two hours. The dissolution of RP
formulations was carried out in phosphate
buffer (0.05M, pH-6.8) for four hours. As
shown in Figure 7A, pure ritonavir exhibited
~23% dissolution at the end of 6 h evaluation
period. Considering the practically insoluble
nature of the molecule, these observations are
expected, and consistent with the results
reported earlier. For the ritonavir: Eudragit®
L100-55 solid dispersions, the rate and extent
of ritonavir release followed a similar path to
that of pure ritonavir for the first two hours (in
acidic conditions). Thereafter, the rate and
extent of ritonavir release from the solid
dispersions were observed to progressively
increase with increasing ratio of Eudragit®
L100-55 in the formulation, up to the ritonavir:

This Journal is © IPEC-Americas Inc

carrier ratio of 1:3. For the formulation with
ritonavir:Eudragit® L100-55 ratio of 1:4, the
rate and extent of ritonavir dissolution was
found to be lower, and similar to the
formulation with the ritonavir: carrier ratio of
1:2. These observations correlated well with the
results obtained from the saturation solubility
studies (Table 1), i.e. aqueous solubility of
ritonavir appeared to increase with increasing
ratio of Eudragit® L100-55, up to the
ritonavir:carrier ratio of 1:3 and lower for
ritonavir:Eudragit® L100-55 ratio of 1:4. The
formulation containing ritonavir:Eudragit®
L100-55 ratio of 1:3 demonstrated a near 100%
release of ritonavir within three hours of
dissolution. This ratio, thus appeared to be an
optimal ratio in regards to enhancing ritonavir
solubility and dissolution. Overall, these solid
dispersions exhibited greater extent of ritonavir
release compared to the native solubility of the
pure ritonavir, possibly due to decreased
crystallinity of ritonavir within the polymer
matrix, and likely formation of a supersaturated
liquid state in the dissolution medium (31). A
reduction in enthalpy of the system is typically
associated with the observed improvement in
the dissolution rates of amorphous solid
dispersions, compared to that of crystalline
materials (32, 33). All the RE formulations
sustained the ritonavir release since Eudragit®
L100-55 is characterized for maintaining
supersaturation (34-36).
Figure 7B shows the comparative dissolution
performance of pure ritonavir and the prepared
solid dispersions of ritonavir with different
ratios of Kolliphor® P1188 in phosphate buffer
(pH-6.8). At the end of the evaluation period,
pure ritonavir exhibited only ~11% dissolution
in the phosphate buffer. Similar to the ritonavir:
Eudragit® L100-55 solid dispersions, the rate
and extent of ritonavir release from these
dispersions was observed to increase with
increasing amounts of Kolliphor® P1188, upto
a ritonavir:carrier ratio of 1:2. Further increases
in the Kolliphor® P188 ratio appeared to
decrease the rate and extent of ritonavir release
from these formulations. These observations
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mirrored those from the saturation solubility
studies (Table 1), where aqueous solubility of
ritonavir was found to be highest in the
formulation with ritonavir:Kolliphor® P1188
ratio of 1:2. Ritonavir:Kolliphor® P188
formulation with a ratio of 1:2 showed ~100%
ritonavir release within 90 min dissolution. This
formulation was thus found to be optimal
considering the goal of improving the
solubility/dissolution of ritonavir. The
lyophilization-induced formation of porous
particles with high surface area, and
subsequently increased surface energies, could
have contributed to the overall increase in
ritonavir solubility/dissolution exhibited by
these solid dispersions. (22, 37). Finally, the
hydrophobic polyoxypropylene center block in
poloxamers assist them in adsorbing strongly
onto the surface of hydrophobic particles (38).
The hydrophilic polyoxyethylene side-chain
thus extends outward from the particle surface,
and stabilizes the particle suspension (39, 40).
The observed decrease in the rate and extent of
ritonavir release at higher Kolliphor® P188
ratios could be attributed to its gel forming
property, resulting in a larger diffusion barrier
for ritonavir (3).
Dissolution efficiency (DE)

Table 2 shows a comparison of the dissolution
efficiencies (DE) of pure ritonavir with that of
the prepared dispersions of ritonavir with
different ratios of Eudragit® L100-55 (RE-1 to
RE-4) or Kolliphor® P188 (RP-1 to RP-4)
carried out in [0.1N HCl/phosphate buffer,
pH-6.8] or phosphate buffer (pH-6.8),
respectively. Depending on the dissolution
media employed, the DE values of pure
ritonavir were observed to be ~11% or ~5.7%.
Consistent with the dissolution study results,
and as expected, the DE values for the
ritonavir: Eudragit® L100-55 solid dispersions
progressively increased with increasing ratio of
Eudragit® L100-55 in the formulation, up to
the ritonavir:carrier ratio of 1:3. For the
formulation with ritonavir:Eudragit® L100-55
ratio of 1:4, the DE value was found to be
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lower, and closer to the formulation with the
ritonavir:carrier ratio of 1:2. The formulation
containing ritonavir:Eudragit® L100-55 ratio of
1:3 demonstrated a significant increase in the
DE value (~41 %, > 3.5-times) compared to
pure ritonavir. Similarly, the DE values of the
solid dispersions was observed to increase with
increasing amounts of Kolliphor® P1188, up to
the ritonavir: carrier ratio of 1:2. Further
increases in the Kolliphor® P188 ratio appeared
to decrease the DE values of these
formulations. Dispersions containing ritonavir:
Kolliphor® P188 in the ratio of 1:2
demonstrated a significant increase in the DE
value (~75%, > 13-times) compared to pure
ritonavir. The increased aqueous solubility of
ritonavir in the prepared solid dispersions is
likely a major contributor for the observed
increase in DE. A decrease in DE observed
with higher polymer ratio in the solid
dispersions can be attributed to the causes
mentioned above.
Table 2 Dissolution efficiency of ritonavir in the
prepared solid dispersions
DRUG:
DISSOLUTION EFFICIENCY
CARRIE
R RATIO RITONAVIR:EUDRAGIT® L 100-55 RITONAVIR:KOLLIPHOR® P188
Pure
Ritonavir

10.95 ± 0.37

5.68 ± 0.23

1:1

33.19 ± 0.89

58.87 ± 1.13

1:2

37.83 ± 0.53

75.17 ± 1.42

1:3

40.75 ± 1.03

52.76 ± 0.95

1:4

35.94 ± 0.97

43.29 ± 0.83

*Values represent mean ± Std. Dev. (n=3)

Fasted versus fed state dissolution

Figure 8 shows the dissolution results for the
optimized dispersions of ritonavir with
Eudragit® L100-55 or Kolliphor® P188 carried
out in biorelevant media viz. FaSSIF (Figure
8A) or FeSSIF (Figure 8B) to assess the
influence of food on the release of ritonavir.
Pure ritonavir showed a significantly slower
dissolution in the FaSSIF media, with ~14%
released at the end of two-hour dissolution
period. However, in the FeSSIF (fed) media,
the rate and extent of ritonavir was ~32% (~2-
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observed to be released in the 120 minute
evaluation period. Eudragit® L100-55, being a
pH-dependent enteric polymer, and the acidic
environment of the FeSSIF media may have
contributed to the slower release of ritonavir.
The optimized dispersions of ritonavir with
Kolliphor® P188 exhibited a significantly faster
rate and extent of ritonavir release in the
FeSSIF media. Nearly 100% of ritonavir was
observed to be released within the first 45
minutes of the dissolution period. These results
demonstrate the importance of selecting a
carrier polymer for formulating solid
dispersions. In the current study, the
performance of ritonavir solid dispersion
containing Kolliphor® P188 appears to be least
influenced by the presence/absence of food.
Ritonavir permeability

Figure 8 In vitro dissolution profiles of the optimized
solid dispersions of ritonavir with Eudragit® L100-55 or
Kolliphor® P188 in (A) FaSSIF medium and (B) FeSSIF
medium.

fold increase) at the end of testing period.
These results are consistent with previously
reported observations regarding the positive
influence of food on the oral absorption of
ritonavir (41).
In the FaSSIF media, the optimized solid
dispersions of ritonavir with Eudragit® L100-55
(RE) showed a significant increase in the rate
and extent of ritonavir release. Nearly 100% of
ritonavir were released within an hour of testing
period. These observations were expected
considering the pH of the FaSSIF media and
the pH-dependent characteristics of the
polymer. The optimized dispersions of ritonavir
with Kolliphor® P188 exhibited a near-linear,
and a significantly higher rate and extent of
ritonavir release, with ~70 % ritonavir released
at the end of the evaluation period. In the
FeSSIF media, the optimized solid dispersions
of ritonavir with Eudragit® L100-55 (RE)
showed a significantly lower rate and extent of
ritonavir release. Only about 7% ritonavir was

This Journal is © IPEC-Americas Inc

Figure 9 shows ritonavir permeability from the
prepared dispersions of ritonavir with different
amounts of Eudragit® L100-55 (Figure 9A, RE1 to RE-4) or Kolliphor® P188 (Figure 9B, RP1 to RP-4) as compared to that of pure
ritonavir. Overall, the permeability profiles of
these solid dispersions followed a pattern
similar to that observed within the in vitro
dissolution studies.
Figure 9A shows the ex vivo permeability
profiles of the prepared solid dispersions of
ritonavir with different ratios of Eudragit®
L100-55 (RE-1 to RE-4). Pure ritonavir
exhibited poor permeability across the intestinal
membrane, with only ~20% traversed at the
end of the 180 minute evaluation period. For
the ritonavir:Eudragit ® L100-55 solid
dispersions, the rate and extent of ritonavir
permeation was observed to progressively
increase with increasing amount of Eudragit®
L100-55 in the formulation, up to the
ritonavir:carrier ratio of 1:3. For the
formulation with ritonavir:Eudragit® L100-55
ratio of 1:4, the rate and extent of ritonavir
permeation was found to be lower, and similar
to the formulation with the ritonavir:carrier
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surfactant and co-emulsifier, is known to be an
inhibitor of P-gp and CYP3A4. This property
of Kolliphor® P188 might have contributed to a
decrease in efflux of ritonavir from intestinal
cells, and resulted in enhancement of ritonavir
transport across the intestinal segment (43).
Preliminary functional stability assessment

The final solid dispersions, i.e.
ritonavir:Eudragit® L100-55 (1:3, RE-3) and
ritonavir:Kolliphor® P188 (1:2, RP-2) were
assessed for a six-month stability 25 °C at 60 %
RH. These formulations were then assessed for
the dissolution and permeability of ritonavir.
These attributes were then compared to the
results obtained prior to storage. Figure 10A
shows a comparison of the dissolution
performance of ritonavir:Eudragit® L100-55
solid dispersion subjected to controlled
conditions for six months with that at day 0.
Figure 9 Ex vivo permeability profiles of the solid
dispersions of ritonavir with different ratios of (A)
Eudragit® L100-55 and (B) Kolliphor® P188, when
compared to pure ritonavir.

ratio of 1:2. The formulation containing
ritonavir:Eudragit® L100-55 ratio of 1:3
demonstrated ~95% of ritonavir permeation at
the end of 180 min evaluation period. For
ritonavir: Kolliphor® P188 solid dispersions
(Figure 9B), the rate and extent of ritonavir
permeation was observed to increase with
increasing amounts of Kolliphor® P188, up to
the ritonavir: carrier ratio of 1:2. Further
increases in the Kolliphor® P188 ratio appeared
to lower the rate and extent of ritonavir
permeation from these formulations.
Ritonavir:Kolliphor® P188 formulation with a
ratio of 1:2 showed ~97% ritonavir permeation
at the end of 3 hours. Within the class of HIV1 protease inhibitors, ritonavir has the lowest
partition coefficient (3.9) (42). The overall
higher permeability of ritonavir observed with
the prepared solid dispersions could be
attributed to the amphiphilic nature of the
carriers. Kolliphor® P188, besides being

This Journal is © IPEC-Americas Inc

Figure 10 Comparison of the (A) in vitro dissolution and
(B) ex-vivo permeability of the optimized solid dispersions
of ritonavir with Eudragit® L100-55, before and after six
months of storage at 25°C/60% RH.
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significant difference was found between the
dissolution performances of both samples. The
results of the comparison of ritonavir
permeability from ritonavir:Kolliphor® P188
solid dispersion stored at controlled conditions
for 180 days with that of initial samples are
shown in Figure 11B. The ritonavir
permeability performance of both samples were
similar, without any significant differences in
the rate and extent of ritonavir permeability
between the samples. While these results
indicate potentially robust and relatively stable
formulation, additional stability studies are
warranted to examine any physico-chemical
changes resulting in the formulations upon
storage. Such studies can also shed light on the
potential recrystallization of the ritonavir in the
solid dispersions upon prolonged storage.
CONCLUSIONS
Figure 11 Comparison of the (A) in vitro dissolution and
(B) ex-vivo permeability of the optimized solid dispersions
of ritonavir with Kolliphor® P188, before and after six
month storage at 25°C at 60% RH.

The rate and extent of dissolution for both
samples were similar, and no significant
differences were observed in their profiles.
Similarly, a comparison of the ritonavir
permeability (Figure 10B) from these samples
showed that the rate and extent of ritonavir
permeation were not influenced by storage
conditions. These results indicate the relative
robustness of the optimized ritonavir:
Eudragit® L100-55 solid dispersion that is
functionally stable.
The dissolution performance of the ritonavir:
Kolliphor® P188 solid dispersion stored for six
months at 25°C/60% RH was similar to that of
the initial solid-dispersion formulation (Figure
11A). At the end of the 120 minute evaluation
period, the sample subjected to 180-day stability
was found to release nearly 100% of ritonavir,
similar to the formulation on day 0. No
This Journal is © IPEC-Americas Inc

The present work explored the feasibility of
optimizing the amounts of a carrier (Eudragit®
L100-55 or Kolliphor® P188) used to prepare
solid dispersions of ritonavir, while increasing
its solubility, dissolution, and permeability. The
prepared solid dispersions were optimized to
achieve maximum functionality at the lowest
carrier-polymer incorporation level. The
analysis of prepared solid dispersions via
photomicroscopy, particle size analysis, thermal
analysis, FTIR, and PXRD supported the
formation of dispersions. The solubility of
ritonavir increased significantly when it was
formulated into a solid dispersion. The results
from the dissolution and permeation studies
revealed a significant improvement in ritonavir
release and permeability from these dispersions,
compared to pure ritonavir. A preliminary
stability assessment study demonstrated the
functional stability of prepared solid
dispersions. A solid dispersion approach can be
successfully implemented to improve the
solubility and permeability of drugs with poor
aqueous solubility via careful selection of carrier
polymers and optimization of formulation
variables.
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